

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. DOI 1450 Alexandria, Virginia 22313-1450 www.unpto.gov

FIRST NAMED APPLICANT ATTORNEY DOCKET NUMBER FILING OR 371 (c) DATE APPLICATION NUMBER

10/672,177

CLEARWATER, FL 33764

09/26/2003

John Lezdey

1435-1

CONFIRMATION NO. 9860

JOHN LEZDEY JOHN LEZDEY & ASSOC. 4625 EAST BAY DR. SUITE 302 **FORMALITIES LETTER**

OC000000012260911

Date Mailed: 04/02/2004

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c) Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- o This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- □ For Rules Interpretation, call (703) 308-4216
- □ To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Mail Stop Missing Parts Replies should be mailed to:

Commissioner for Patents

P.O. Box 1450

Alexandria VA 22313-1450

A copy of this notice <u>MUST</u> be returned with the reply.

Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE



In the United States Patent and Trademark Office

Applicant:

Lezdey

Serial No.:

10/672,177

Filed:

09/26/2003

For:

DNA for Expression of Alpha1-Antitrypsin in Methylotropic Yeast

Mail Stop Missing Parts

Commissioner for Patents

P.O. Box 1450

Alexandria, VA. 22313-1450

Response

Responsive to the Notice mailed 12/22/2003.

In response to the request to file a sequence listing, applicants request pursuant to 37 C.F.R. 1.821(e) that the disc and readable form filed in application no. 09/526,401 and later filed in application no. 09/981,073 of which this application is a continuation-in-part be made of record in the present application.

No new matter is being submitted.

Enclosed is a copy of the Notice to Comply.

Respectfully submitted,

John Lezdey

Registration No. 22,735

John Lezdey & Associates 4625 East Bay Drive

Suite 302

Clearwater, FL. 33764

(727) 539-0633



Remarks

An Official Filing Receipt and Notice of Sequence Requirement was previously submitted as seen by the attached.

No new sequence is required because applicant has complied with 37 C.F.R. 1821(e).

Respectfully submitted, JOHN LEZDEY & ASSOCIATES

John Lezdey

Registration No.: 22,735 4625 East Bay Drive

Suite 302

Clearwater, FL 33764

(727) 539-0633